Drugs / EDRALBRUTINIB
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05560360 | Nov → Dec 2022 | B-cell neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05095337 | Jun → Jul 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04649723 | Nov → Dec 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04455100 | Jul → Aug 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04395053 | Jun → Jul 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04291846 | May → Jun 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03671590 | Sep 2018 → May 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | TG Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03668509 | Sep 2018 → Jan 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03664297 | Feb 2018 → Dec 2023 | neoplasm of mature B-cells | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04948788 | Oct 2021 → Apr 2023 | B-cell non-Hodgkin lymphoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04670770 | Jan 2021 → Aug 2022 | neuromyelitis optica | Reistone Biopharma Company Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05136456 Comparator | Dec 2021 → Aug 2023 | idiopathic membranous glomerulonephritis | Reistone Biopharma Company Limited | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDRALBRUTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650338 ↗ |
| Known as | SHR1459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04291846 ↗ |
| Known as | TG-1701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03671590 ↗ |
| Action | Inhibit | “by inhibiting the phosphorylation of BTK” NCT03664297 ↗ |
| Modality | Small molecule | “SHR1459 is a selective small molecule BTK inhibitor” NCT03664297 ↗ |
| Route | Oral | “oral adminstration of SHR1459, dose 1” NCT03668509 ↗ |
| Target | BTK | “by inhibiting the phosphorylation of BTK” NCT03664297 ↗ |